Oxford Ledge
Search
Acrivon Therapeutics, Inc. Common Stock (NASDAQ: ACRV) is a biotechnology company trading at $1.49 (−2.0% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 15:17 UTC.
Acrivon is a clinical-stage biopharmaceutical company that develops precision cancer medicines using its proprietary AP3 platform, which measures how drugs affect protein signaling pathways within intact tumor cells to identify which patients will benefit from treatment. The company's approach addresses limitations of genetics-based precision medicine by analyzing tumor-specific biochemical pathways rather than relying solely on genetic mutations, making it applicable to a broader range of cancers including solid tumors.
Summarized from Acrivon Therapeutics, Inc. Common Stock’s SEC filings · Read the filing ↗
| Quote | |
| Price | $1.49 |
| Change (1D) | -0.03 (-1.97%) |
| Volume | 318.4K shares |
| 52-week range | $1.15 – $3.56 |
| Returns | |
| 52-week return | +29.6% |
Acrivon is a clinical-stage biopharmaceutical company that develops precision cancer medicines using its proprietary AP3 platform, which measures how drugs affect protein signaling pathways within intact tumor cells to identify which patients will benefit from treatment.
ACRV trades at $1.49, as of 2026-07-14.
Acrivon Therapeutics, Inc. Common Stock's most recent SEC filing on record is a 8-K filed 2026-06-17. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-07-14 15:17 UTC. This page is also available as JSON at /api/data?ticker=ACRV and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACRV and 3,500+ tickers.
Create a free account — keep ACRVGET /api/data?ticker=ACRV
This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt